title: Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids.
abstract: The adverse effect of disease and chronic corticosteroid therapy on bone mineral density (BMD) in patients with systemic lupus erythematosus (SLE) has been reported in several studies of Caucasian populations. As the factors controlling bone homeostasis may be different in Asian populations, we measured BMD in 52 pre-menopausal Chinese women (mean age 34.1 +/- 8.0 yr) with SLE (mean disease duration 6.4 +/- 4.5 yr) treated with prednisone (mean daily dose 11.4 +/- 10.8 mg/day). Lumbar spine, hip (total and subregions) and total body BMDs were measured in the SLE patients using dual-energy X-ray absorptiometry (DEXA), and compared with those from healthy controls matched for age, sex and body mass index. Compared to controls, SLE patients were found to have lower BMD (g/cm2) at several sites: the lumbar spine (0.98 vs 0.90, P = 0.001), Ward's triangle (0.72 vs 0.67, P = 0.03), total body (1.04 vs 1.01, P = 0.04) and total hip (0.87 vs 0.82, P = 0.05). There was no correlation between BMD at any region and duration of disease, activity of disease or prednisone therapy (mean daily dose, cumulative dose or treatment duration). When BMDs were compared between controls and SLE patients, subgrouped according to those not on calcium and those arbitrarily receiving calcium supplements (1 g/day), significantly lower BMDs were found in those not on calcium compared to both controls and SLE patients on calcium. BMDs in SLE patients on calcium were not different from those in controls. The low prevalence of osteoporosis in our SLE patients (4-6%) suggests significant loss of BMD in Chinese SLE patients on corticosteroid therapy is less than that reported in Caucasians (12-18%).
authors.affiliation: Department of Medicine, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin.
authors.forename: E K
authors.initials: EK
authors.lastname: Li
authors.forename: L S
authors.initials: LS
authors.lastname: Tam
authors.forename: R P
authors.initials: RP
authors.lastname: Young
authors.forename: G T
authors.initials: GT
authors.lastname: Ko
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: E M
authors.initials: EM
authors.lastname: Lau
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D044466:Asian People; D015519:Bone Density / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D002136:Calcium, Dietary / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D005260:Female; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000208:ethnology / Q000378:metabolism; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced* / Q000188:drug therapy / Q000208:ethnology; D017697:Premenopause; D015995:Prevalence
chemical_list: D000305:Adrenal Cortex Hormones; D002136:Calcium, Dietary; D002118:Calcium